Non-Invasive Determination of Fetal Chromosome Abnormalities
The overall significance of this study is to develop a laboratory developed test (LDT) to use a new marker in the maternal blood to better identify pregnancies that have a child with a chromosome abnormality such as Down syndrome (trisomy 21), Edward's syndrome (trisomy 18), Patau syndrome (trisomy 13), Klinefelter syndrome, (47, XXY), and other chromosome abnormalities. Accomplishing that task would reduce the need for invasive amniocentesis and CVS procedures.
100 Clinical Results associated with Lenetix Medical Screening Laboratory, Inc.
0 Patents (Medical) associated with Lenetix Medical Screening Laboratory, Inc.
100 Deals associated with Lenetix Medical Screening Laboratory, Inc.
100 Translational Medicine associated with Lenetix Medical Screening Laboratory, Inc.